文献速递其他结缔组织病

幼年皮肌炎中肌源性祖细胞呈现I型干扰素驱动的促血管生成特性及分子特征

Myogenic Progenitor Cells Exhibit Type I Interferon-Driven Proangiogenic Properties and Molecular Signature During Juvenile Dermatomyositis.
PubMed 文献 · Arthritis Rheumatol · 2017-11-28

该研究探讨幼年皮肌炎(JDM)中肌源性前体细胞(MPCs)是否通过I型干扰素(IFN)调控血管重塑。采用人细胞共培养和转录组分析,发现JDM来源MPCs高表达促血管生成分子特征,I型IFN为其主调控因子,且MPCs自身合成I型IFN并与疾病严重程度相关。结论提示JDM中存在I型IFN通路激活MPCs促血管生成功能的新机制。

要点

  • JDM来源MPCs在共培养中表现出高促血管生成特性并伴血管生成分子特征表达。
  • I型IFN是JDM来源MPCs中上调基因的主调控因子,可重现其分子模式和促血管生成功能。
  • JDM肌肉中MPCs合成I型IFN和主要促血管生成分子,且与血管病变严重程度相关。

核心结论

  • JDM中存在新的I型IFN通路,激活MPCs产生血管生成效应分子,触发其促血管生成功能以促进血管恢复和肌肉重建。

研究设计与样本

  • 采用人细胞共培养分析JDM患者、DMD患者(血管重塑对照)和健康对照的血管生成特性。
  • 对肌肉来源MPCs进行转录组分析,并对肌肉活检样本进行I型IFN的组织学分析。

主要发现

  • 人细胞共培养显示JDM患者MPCs具有高度促血管生成特性,并伴随血管生成分子特征表达。
  • 新鲜分离的JDM来源MPCs转录组分析显示I型IFN是上调基因的主调控因子。
  • 用I型IFN处理正常MPCs可重现JDM来源MPCs的分子模式和促血管生成功能。
  • 体内组织学显示JDM肌肉中MPCs合成I型IFN和主要促血管生成分子。
  • 来自强血管病变JDM肌肉的MPCs产生更高水平I型IFN,且与疾病严重程度相关。

临床怎么用

  • 提示MPCs来源的I型IFN信号可能作为JDM血管病变和肌肉修复的潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Juvenile dermatomyositis (JDM) is an inflammatory pediatric myopathy characterized by focal capillary loss in muscle, followed by progressive recovery upon adequate treatment with immunomodulating drugs, although some patients remain refractory to treatment. While the underlying mechanism of capillary depletion remains uncertain, recent studies have identified an up-regulation of type I interferon (IFN) expression specific to JDM. Given that myogenic precursor cells (MPCs) exert proangiogenic activity during normal skeletal muscle regeneration, we hypothesized that they may also modulate vascular remodeling/angiogenesis during JDM. The aim of this study was to investigate that hypothesis. METHODS: Human cell cocultures were used to analyze angiogenic properties in patients with JDM, patients with Duchenne's muscular dystrophy (DMD) (control patients for vascular remodeling), and healthy control subjects. Transcriptome analysis was used to examine muscle-derived MPCs. Histologic analysis of type I IFN in muscle biopsy samples was also performed. RESULTS: Using human cell cocultures, we showed highly angiogenic properties of MPCs from JDM patients in association with the expression of an angiogenic molecular signature. Transcriptome analysis of MPCs freshly isolated from muscle samples revealed type I IFN as the master regulator of the most up-regulated genes in JDM-derived MPCs. Functionally, treatment of normal MPCs with type I IFN recapitulated the molecular pattern and the proangiogenic functions of JDM-derived MPCs. In vivo histologic investigation showed that MPCs synthesized type I IFN and major proangiogenic molecules in JDM muscle. Moreover, MPCs derived from JDM muscles that were characterized by strong vasculopathy produced higher levels of type I IFN, confirming MPCs as a cellular source of type I IFN during JDM, and this correlated with the severity of the disease. CONCLUSION: These results demonstrate a new type I IFN pathway in JDM that activates the production of angiogenic effectors by MPCs, triggering their proangiogenic function to promote vessel recovery and muscle reconstruction.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Gitiaux C, Latroche C, Weiss-Gayet M, et al. Myogenic Progenitor Cells Exhibit Type I Interferon-Driven Proangiogenic Properties and Molecular Signature During Juvenile Dermatomyositis. Arthritis Rheumatol. 2017. PMID: 28941175. doi:10.1002/art.40328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。